NCT02514824View on ClinicalTrials.gov

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

MLN0128

Investigational mTOR kinase inhibitor

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER